CL2011002814A1 - Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. - Google Patents

Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar.

Info

Publication number
CL2011002814A1
CL2011002814A1 CL2011002814A CL2011002814A CL2011002814A1 CL 2011002814 A1 CL2011002814 A1 CL 2011002814A1 CL 2011002814 A CL2011002814 A CL 2011002814A CL 2011002814 A CL2011002814 A CL 2011002814A CL 2011002814 A1 CL2011002814 A1 CL 2011002814A1
Authority
CL
Chile
Prior art keywords
dimethyl
morpholin
phenyl
butyramide
depressive
Prior art date
Application number
CL2011002814A
Other languages
English (en)
Spanish (es)
Inventor
Svend Treppendahl
Karin Lopez De Diego Heidi Lilporp
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2011002814A1 publication Critical patent/CL2011002814A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2011002814A 2009-05-11 2011-11-10 Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. CL2011002814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
CL2011002814A1 true CL2011002814A1 (es) 2012-04-13

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002814A CL2011002814A1 (es) 2009-05-11 2011-11-10 Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar.

Country Status (23)

Country Link
EP (1) EP2430008A2 (de)
JP (1) JP2012526152A (de)
KR (1) KR20120022934A (de)
CN (1) CN102459208A (de)
AR (1) AR076556A1 (de)
AU (1) AU2010246724B2 (de)
BR (1) BRPI1013930A2 (de)
CA (1) CA2761383A1 (de)
CL (1) CL2011002814A1 (de)
CO (1) CO6460741A2 (de)
CR (1) CR20110590A (de)
DO (1) DOP2011000351A (de)
EA (1) EA201171381A1 (de)
GE (1) GEP20146006B (de)
IL (1) IL216148A0 (de)
MA (1) MA33351B1 (de)
MX (1) MX2011011885A (de)
NZ (1) NZ596738A (de)
SG (1) SG175968A1 (de)
TN (1) TN2011000557A1 (de)
TW (1) TW201041857A (de)
WO (1) WO2010130260A2 (de)
ZA (1) ZA201108112B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
EP2185149A1 (de) * 2007-08-01 2010-05-19 H. Lundbeck A/S Verwendung von kncq-kaliumkanal-öffnern zur verringerung von symptomen oder zur behandlung von erkrankungen oder störungen mit unterbrechung des dopaminergen systems

Also Published As

Publication number Publication date
SG175968A1 (en) 2011-12-29
IL216148A0 (en) 2012-01-31
MA33351B1 (fr) 2012-06-01
TW201041857A (en) 2010-12-01
BRPI1013930A2 (pt) 2019-09-24
CA2761383A1 (en) 2010-11-18
NZ596738A (en) 2013-04-26
CN102459208A (zh) 2012-05-16
EP2430008A2 (de) 2012-03-21
WO2010130260A2 (en) 2010-11-18
JP2012526152A (ja) 2012-10-25
MX2011011885A (es) 2011-12-06
TN2011000557A1 (en) 2013-05-24
CO6460741A2 (es) 2012-06-15
AR076556A1 (es) 2011-06-22
KR20120022934A (ko) 2012-03-12
WO2010130260A3 (en) 2011-06-16
GEP20146006B (en) 2014-01-10
AU2010246724A1 (en) 2011-12-08
EA201171381A1 (ru) 2012-05-30
CR20110590A (es) 2012-02-22
WO2010130260A9 (en) 2012-10-18
ZA201108112B (en) 2013-01-30
DOP2011000351A (es) 2012-01-31
AU2010246724B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2008001818A1 (es) Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2015002897A1 (es) Inhibidores de bace1
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil